Anika Therapeutics (ANIK) FCF Margin: 2010-2025
Historic FCF Margin for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to 17.91%.
- Anika Therapeutics' FCF Margin rose 506.00% to 17.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year increase of 151.00%. This contributed to the annual value of -1.94% for FY2024, which is 403.00% up from last year.
- Per Anika Therapeutics' latest filing, its FCF Margin stood at 17.91% for Q3 2025, which was up 405.25% from -5.87% recorded in Q2 2025.
- Anika Therapeutics' 5-year FCF Margin high stood at 73.48% for Q4 2022, and its period low was -62.02% during Q4 2023.
- In the last 3 years, Anika Therapeutics' FCF Margin had a median value of -6.66% in 2024 and averaged -8.19%.
- In the last 5 years, Anika Therapeutics' FCF Margin soared by 6,415bps in 2022 and then plummeted by 13,551bps in 2023.
- Over the past 5 years, Anika Therapeutics' FCF Margin (Quarterly) stood at 9.34% in 2021, then surged by 6,415bps to 73.48% in 2022, then slumped by 13,551bps to -62.02% in 2023, then surged by 6,292bps to 0.90% in 2024, then surged by 506bps to 17.91% in 2025.
- Its FCF Margin was 17.91% in Q3 2025, compared to -5.87% in Q2 2025 and -11.29% in Q1 2025.